Literature DB >> 11557244

The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals.

T Habon1, E Szabados, G Kesmarky, R Halmosi, T Past, B Sumegi, K Toth.   

Abstract

OBJECTIVE: Previous studies have reported that the beta and alpha adrenoceptor blocker carvedilol has unique protective effects on free radical-induced myocardial injury. The aim of this study was to examine how carvedilol regulates reactive-oxygen-species-mediated signaling and decreases red blood cell membrane damage in heart perfusion and in a rheological model.
METHODS: The ischemia-reperfusion-induced oxidative cell damage, and changes in the intracellular signaling mediated by reactive oxygen species and peroxynitrite were studied on rat hearts in a Langendorff perfusion system (n=15). The effect of carvedilol on red blood cell suspension viscosity (hematocrit: 60%) incubated with free radical generator (phenazine methosulphate) was also investigated (n=10). The measurements were performed on a capillary viscosimeter.
RESULTS: In both studies a protective effect of carvedilol was found, as the decrease of red blood cell suspension viscosity and K(+) concentration in the supernatant indicated. Carvedilol significantly decreased the ischemia-reperfusion-induced free radical production and the NAD(+) catabolism and reversed the poly- and mono(ADP-ribosyl)ation. Carvedilol also decreased the lipid peroxidation and membrane damages as determined by free malondialdehyde production and the release of intracellular enzymes. The self ADP-ribosylation of isolated poly(ADP-ribose) polymerase was also significantly inhibited by carvedilol.
CONCLUSION: Our results show that carvedilol can modulate the reactive-oxygen-species-induced signaling through poly- and mono(ADP-ribosyl)ation reactions, the NAD(+) catabolism in postischemic perfused hearts and has a marked scavenger effect on free radical generator-induced red blood cell membrane damage. All these findings may play an important role in the beneficial effects of carvedilol treatment in different cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557244     DOI: 10.1016/s0008-6363(01)00359-5

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  4 in total

1.  Dynamics of Metabolic and Oxidative Parameters of Erythrocytes during Treatment of Chronic Heart Failure with Molecular Hydrogen.

Authors:  A V Deryugina; D A Danilova; A A Skokova; Yu D Brichkin; V V Pichugin; A P Medvedev; M V Ryazanov; S A Fedorov
Journal:  Bull Exp Biol Med       Date:  2022-10-10       Impact factor: 0.737

2.  Effects of carvedilol on cardiomyocyte apoptosis and gene expression in vivo after ischemia-reperfusion in rats.

Authors:  Hesong Zeng; Xiaochun Liu; Huayue Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

3.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

4.  Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Sajee Alummoottil; Prashilla Soma; Antoinette V Buys; Douglas B Kell
Journal:  Cardiovasc Diabetol       Date:  2015-03-08       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.